EXTENDED REPORT

Selective T cell receptor decrease in peripheral blood T lymphocytes of patients with polymyalgia rheumatica and giant cell arteritis

M Lopez-Hoyos, M J Bartolome-Pacheco, R Blanco, V Rodriguez-Valverde, V M Martinez-Taboada


Objectives: To investigate the phenotype and T cell receptor (TCR) use in peripheral blood T cells in patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA).

Methods: Circulating T lymphocyte phenotype and TCR repertoire were studied by flow cytometry using specific monoclonal antibodies in 23 healthy controls and 37 patients with PMR/GCA.

Results: Patients with active PMR/GCA showed an inverse relation between naive and memory CD4+ T cells and unchanged expression of activation surface markers compared with controls. CD4+ TCR BV expansions were seen in 12 (52%) controls and in 8 (22%) patients with active disease (p = 0.03). Within the CD8+ subset, the frequency of expansions was similar between groups. Most T cell expansions remained stable over time. Seventeen of the 23 patients with active PMR/GCA disclosed a simultaneous CD4+ and CD8+ T cell depletion for at least one particular BV family with a clear predominance of BV52/53.

Conclusions: The phenotype of circulating T cells in patients with PMR/GCA is similar to that found in aged healthy subjects, except for the surface markers of naive and memory cells and a striking non-activated phenotype. Specific BV expansions in CD4+ and CD8+ T cells, which remain stable over time, are frequent in aged subjects, including patients with PMR/GCA. TCR BV changes in patients with active disease seem to be also age related, except for the significant decrease in certain BV families in both CD4+ and CD8+ T cell subsets, which may favour the participation of a superantigen stimulation in PMR/GCA.

Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two closely related syndromes affecting elderly people.1 GCA is a granulomatous vasculitis affecting medium and large sized arteries, and the inflammatory lesions are characterised by the presence of mononuclear cells, multinuclear giant cells, and fragmentation of the internal elastic laminae.4–6 Around 50% of patients with GCA have PMR, a clinical syndrome characterised by pain and stiffness in the neck, shoulder, and pelvic girdle.7 The main factors that determine the development of a full vasculitic syndrome are yet unknown.7 GCA and PMR represent HLA-DR4 associated diseases.6–7 The HLA genes may affect disease pathogenesis through several mechanisms. One of the major biological functions of the HLA molecule is the antigen presentation to T cells, the so-called peptide selection model. In GCA, this model would shape the selection of the T cell repertoire and determine disease-related antigens, and it is considered the best example of a T cell mediated vasculitis.6–11 CD4+ T cells are one of the dominant cellular types in the vasculitic lesions, which also express activation surface markers, and undergo clonal proliferation in the inflammatory lesions of the temporal artery.8–11 However, much less is known about the role of circulating T cells in patients with GCA and PMR. One of the most striking features of these two conditions is the development of the disease, almost exclusively, in people aged over 50 years. Thus, there is evidence for age associated changes in the circulating T cell compartment that might favour the development of autoimmune disorders in the elderly.14–17

The purpose of this study was to investigate the phenotype and TCR use in CD4+ and CD8+ peripheral blood T cells in a large sample of patients with PMR and GCA.

PATIENTS AND METHODS

Patients and controls

During a two year period, 23 consecutive patients with active PMR/GCA before steroid treatment and 14 patients with PMR/GCA in clinical remission after steroid treatment (mean (SD) time after diagnosis 2.4 (1.9) years) were recruited into the study. Six of the 14 patients with controlled disease had not been receiving steroids for at least six months, and the remaining eight patients continued to receive low dose prednisone. In four patients with active PMR/GCA, follow up samples were taken after six months of treatment, when

Abbreviations: GCA, giant cell arteritis; mAb, monoclonal antibody; MHC, major histocompatibility cell; PCR, polymerase chain reaction; PMR, polymyalgia rheumatica; TCR, T cell receptor

www.annrheumdis.com
the patients were in clinical remission. Twenty three healthy controls matched for age and race were studied in parallel. Table 1 summarises the main clinical and laboratory characteristics of the study cohort. PMR was diagnosed according to the criteria proposed by Chuang et al. All the patients with GCA had a positive temporal artery biopsy. Corticosteroid treatment for PMR was started with prednisone 40–60 mg daily (15–20 mg three times a day). After initial control of the disease, the dose of corticosteroids was reduced according to clinical disease activity.

**Routine laboratory assessment**

All the blood samples were collected between 7.30 am and 9.30 am, before the morning dose of the daily treatment. Total white cell, lymphocyte and platelet counts, haemoglobin, erythrocyte sedimentation rate and C reactive protein were measured by routine techniques (table 1).

**Preparation of cells and HLA typing**

Peripheral blood mononuclear cells were purified from EDTA venous blood by Ficoll gradient centrifugation (Amersham Pharmacia Biotech, Uppsala, Sweden). DNA was extracted with DNAzol reagent (InVitrogen, Grand Island, NY) according to the manufacturer’s instructions. Patients and controls were characterised for their HLA-DRB1 alleles by allele-specific polymerase chain reaction (PCR) amplification with a Dynal All Set sequence-specific primers (SSP; Dynal AS, Oslo, Norway).

**FACS analysis**

Peripheral blood T lymphocyte phenotype and TCR BV usage were determined by flow cytometry in whole blood samples. The following monoclonal antibodies (mAbs) were used for staining: FITC conjugated mAb specific for CD7, CD45RA, CD45RO, HLA-DR (Pharmigen, San Diego, CA), CD25, CD28, CD57, BV2 (Labgen, Labclinics, Barcelona), BV3S1, BV5S1, BV5S2/S3, BV6S7, BV8, BV13S1/13S3 (T cell diagnostics, Woburu, MA), BV12 and BV17 (Endogen, Woburu, MA), phycoerythrin conjugated anti-CD4 and anti-CD8, and FITC conjugated anti-CD3 (Becton Dickinson, San Jose, CA). Whole blood samples were stained within six hours of venepuncture with two colour direct immunofluorescence reagents for 30 minutes at 4°C. Thereafter, erythrocytes were lysed using FACS Brand Lysing Solution (Becton Dickinson). After two washings with phosphate buffered saline, cells were resuspended and analysed on the day of processing using a Becton Dickinson FACScalibur and CellQuest software. Twenty thousand events were analysed. TCR BV-specific expansion was defined as BV specificities expressed as a value of more than 20% or at a frequency greater than the mean+3SD of a young healthy population.

**Statistical analysis**

Analysis was performed with the STATISTICA software package for Macintosh (Macintosh, Apple Computer Inc, Cupertino, CA, USA). We used the two tailed Student t test for the continuous variables with a normal distribution, and non-parametric tests (median and Mann-Whitney U test) for those without a normal distribution. The χ2 test or the Fisher exact test was used to compare the dichotomous variables.

**RESULTS**

**Demographic features and main laboratory data**

Table 1 shows that patients with active disease had a higher leucocyte count (p = 0.001) and a lower percentage of total lymphocytes (p = 0.01) than healthy controls. As expected, all the measures reflecting the inflammatory process were higher in patients with active disease than in healthy controls and patients in clinical remission (p<0.05).

**Circulating lymphocyte subsets**

The percentages and absolute numbers of the main lymphocyte subsets were comparable except for the percentage of CD4+ T cells between patients with active and controlled disease (table 2). Despite a higher percentage of CD4+ T cells in patients with active untreated disease (p = 0.03), absolute counts and the CD4/CD8 ratios were similar between the different groups. In agreement with a previous report,20 percentages and absolute numbers of CD8+ T cells were similar between the different study groups. The frequencies of NK cells (CD3–CD16+CD56+) and T cells with a killer phenotype (CD3+CD16+CD56+) were also similar in patients and controls.

**Peripheral T lymphocyte phenotype**

Analysis showed that the T cell phenotype in both groups of patients was very similar (table 3). A slight but significant increase in the percentage of CD4+CD7+ T cells (p = 0.03) was seen in patients with active PMR/GCA compared with healthy controls. Although other markers have been recently

---

**Table 1** Main demographic and routine laboratory data in patients with polymyalgia rheumatica (PMR)/giant cell arteritis (GCA) and healthy controls

<table>
<thead>
<tr>
<th></th>
<th>Healthy controls (n = 23)</th>
<th>PMR/GCA before treatment (n = 23)</th>
<th>PMR/GCA after treatment (n = 14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>73 (8)</td>
<td>73.2 (6.9)</td>
<td>74 (6.2)</td>
</tr>
<tr>
<td>Sex (F, female; M, male)</td>
<td>14/9</td>
<td>11/12</td>
<td>9/5</td>
</tr>
<tr>
<td>PMR/GCA (n)</td>
<td>0/0</td>
<td>18/5</td>
<td>6/8</td>
</tr>
<tr>
<td>Leucocytes (&gt;10⁶ cells/l)</td>
<td>5.6 (1.1)*</td>
<td>7.4 (1.9)*</td>
<td>8.8 (2.6)</td>
</tr>
<tr>
<td>Lymphocytes (%)</td>
<td>30.5 (6.1)*</td>
<td>24.3 (8.8)*</td>
<td>25.2 (9.9)</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate (%)</td>
<td>30.5 (6.1)%</td>
<td>30.7 (6.1)</td>
<td>30.6 (6.1)</td>
</tr>
<tr>
<td>Haemoglobin (g/l)</td>
<td>137 (18)*</td>
<td>125 (18)*</td>
<td>138 (16)</td>
</tr>
<tr>
<td>Leucocyte count</td>
<td>0.41 (0.06)</td>
<td>0.38 (0.05)</td>
<td>0.41 (0.05)</td>
</tr>
<tr>
<td>Packed cell volume</td>
<td>275 (108)*</td>
<td>275 (108)*</td>
<td>275 (108)*</td>
</tr>
<tr>
<td>Platelets (&gt;10⁶ cells/l)</td>
<td>190 (35)*</td>
<td>190 (35)*</td>
<td>190 (35)*</td>
</tr>
<tr>
<td>ESR (mm/1st h)</td>
<td>7.5 (5.3)*</td>
<td>48.5 (34.5)*</td>
<td>14.4 (13.5)*</td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>4 (1)*</td>
<td>43 (37)*</td>
<td>6 (6)*</td>
</tr>
</tbody>
</table>

The results are expressed as mean (SD).

**Table 2** Main circulating T lymphocyte subsets in patients with PMR/GCA and healthy controls

<table>
<thead>
<tr>
<th></th>
<th>Healthy controls</th>
<th>PMR/GCA before treatment</th>
<th>PMR/GCA after treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD3 (CD3+)</td>
<td>68.4 (10.4)</td>
<td>71.1 (8.2)</td>
<td>71 (12.5)</td>
</tr>
<tr>
<td>CD4 (CD4+)</td>
<td>40 (8.7)</td>
<td>44.8 (8.3)*</td>
<td>37.5 (11)*</td>
</tr>
<tr>
<td>CD8 (CD8+)</td>
<td>28.4 (8.9)</td>
<td>26.3 (11.3)</td>
<td>27.5 (12.6)</td>
</tr>
<tr>
<td>CD4/CD8 ratio</td>
<td>1.7 (1.4)</td>
<td>2.1 (1.2)</td>
<td>1.9 (1.6)</td>
</tr>
<tr>
<td>CD3+/CD16+CD56+</td>
<td>3.8 (4)</td>
<td>2.1 (1.2)</td>
<td>1.9 (1.6)</td>
</tr>
<tr>
<td>CD3–/CD16+CD56+</td>
<td>14.3 (7.2)</td>
<td>13 (4)</td>
<td>17.8 (6.5)</td>
</tr>
</tbody>
</table>

The results are expressed as mean (SD) percentage and absolute numbers are shown in square brackets.

*PMR/GCA before corticosteroid treatment versus PMR/GCA after treatment p < 0.05.
Table 3  Phenotype of circulating T lymphocyte subsets in patients with PMR/GCA and healthy controls

<table>
<thead>
<tr>
<th></th>
<th>Healthy controls</th>
<th>PMR/GCA before treatment</th>
<th>PMR/GCA after treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4/CD7</td>
<td>79.7 (9.2)*</td>
<td>85.3 (8)*</td>
<td>81.8 (11.1)</td>
</tr>
<tr>
<td>CD4/CD28</td>
<td>87.7 (13.9)</td>
<td>92.5 (9.9)</td>
<td>86.4 (16.7)</td>
</tr>
<tr>
<td>CD4/CD57</td>
<td>10.7 (10.9)</td>
<td>6.5 (8)</td>
<td>10.3 (10.2)</td>
</tr>
<tr>
<td>CD4/CD45RA</td>
<td>30 (11.7)*</td>
<td>40 (14.9)*</td>
<td>36.2 (17)</td>
</tr>
<tr>
<td>CD4/CD45RO</td>
<td>72.4 (13.1)*</td>
<td>60.3 (14.7)*</td>
<td>62.7 (17.1)</td>
</tr>
<tr>
<td>CD4/CD25</td>
<td>4.9 (2.4)</td>
<td>5.5 (4.1)</td>
<td>4.8 (3.7)</td>
</tr>
<tr>
<td>CD4/HLA-DR</td>
<td>3.3 (1.9)</td>
<td>2.3 (1.4)</td>
<td>4.6 (4.8)</td>
</tr>
<tr>
<td>CD8/CD7</td>
<td>89.2 (6.3)</td>
<td>91.6 (9.9)</td>
<td>89.6 (13.3)</td>
</tr>
<tr>
<td>CD8/CD28</td>
<td>35.8 (12.2)</td>
<td>33.6 (14.8)</td>
<td>26.6 (14.5)</td>
</tr>
<tr>
<td>CD8/CD57</td>
<td>49 (13.1)</td>
<td>43.8 (17.2)</td>
<td>50.3 (17.5)</td>
</tr>
<tr>
<td>CD8/CD45RA</td>
<td>64.3 (7.8)</td>
<td>68.8 (10.9)</td>
<td>75 (14.6)</td>
</tr>
<tr>
<td>CD8/CD45RO</td>
<td>39.6 (8.6)</td>
<td>34.5 (10.6)</td>
<td>28.9 (18.8)</td>
</tr>
<tr>
<td>CD8/CD25</td>
<td>1.3 (0.8)</td>
<td>1.3 (1.1)</td>
<td>1.2 (0.7)</td>
</tr>
<tr>
<td>CD8/HLA-DR</td>
<td>5.3 (3.4)</td>
<td>3.4 (2.3)</td>
<td>3.6 (4.6)</td>
</tr>
<tr>
<td></td>
<td>[24 (18)]*</td>
<td>[34 (20)]*</td>
<td>[30 (30)]*</td>
</tr>
</tbody>
</table>

The results are expressed as mean (SD) percentage and absolute numbers are shown in square brackets.

*Healthy controls versus PMR/GCA before corticosteroid treatment; p < 0.05

of the total T cell repertoire. Patients with active disease had a higher percentage of CD4+/BV3+ T cells (p = 0.02) than healthy controls. However, there were no differences between patients and controls in any of the TCR BV families of the CD8+ subset (table 4). Furthermore, no significant difference between patients with active and controlled disease was found (data not shown).

Table 4  TCR BV expression on T cells in patients with PMR/GCA and healthy controls

<table>
<thead>
<tr>
<th>mAb</th>
<th>CD4+ T cells</th>
<th>CD8+ T cells</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Healthy controls</td>
<td>PMR/GCA before treatment</td>
</tr>
<tr>
<td>BV2</td>
<td>10.1 (1.9)</td>
<td>10.3 (1.9)</td>
</tr>
<tr>
<td>BV3</td>
<td>4 (2.1)</td>
<td>5.5 (3.5)</td>
</tr>
<tr>
<td>BV552/53</td>
<td>4.4 (7.6)</td>
<td>2.4 (5.5)</td>
</tr>
<tr>
<td>BV51</td>
<td>5.1 (1.4)</td>
<td>5.3 (1.3)</td>
</tr>
<tr>
<td>BV67</td>
<td>4.6 (1.8)</td>
<td>5 (2.6)</td>
</tr>
<tr>
<td>BV8</td>
<td>5.1 (4.8)</td>
<td>4 (1.2)</td>
</tr>
<tr>
<td>BV12</td>
<td>2.1 (1.1)</td>
<td>2.6 (1.7)</td>
</tr>
<tr>
<td>BV13.1</td>
<td>7.6 (5.7)</td>
<td>6.7 (3.1)</td>
</tr>
<tr>
<td>BV17</td>
<td>6.4 (3.2)</td>
<td>6.1 (1.3)</td>
</tr>
</tbody>
</table>

The results are expressed as mean (SD).

TCR BV expansions
We identified T cell expanded populations in both patients and controls. CD4+ TCR BV expansions were seen in 12/23 (52%) healthy subjects (1.1 expansion/individual) and in 5/23 (22%) patients with active disease (1.4 expansion/individual). The difference between these two groups was significant (p = 0.03) (fig 1). Patients with PMR/GCA with controlled disease after steroid treatment showed CD4+ TCR BV expansions in 7/14 (50%) cases, with a total of nine expansions (1.3 expansion/individual), although this difference was not significant compared with patients with active disease (p = 0.07). Within the CD8+ subset, expansions were present in 11 (48%) healthy aged controls (1.1 expansion/individual) and in 11 (48%) patients with active disease (1.6 expansion/individual) (p = NS). Patients with PMR/GCA after steroid treatment showed CD8+ T cell expansions in 7 (50%) patients (1.7 expansion/individual).
TCR expansions of one or more BV families were seen in patients and controls. Figure 2 shows the distributions of such expansions. Within the CD4+ and CD8+ subsets the distribution of the BV expansions followed a random pattern with no significant differences between healthy controls and both groups of patients. Although the sample size was probably too small to for definite conclusions to be drawn, no apparent associations between BV expansions and a particular HLA-DRB1 allele were found (data not shown).

Stability of TCR BV expansions

In four patients we had the opportunity to study blood samples during the active phase of the disease before steroid treatment and after six months of treatment while they were in clinical remission. Before steroid treatment these four patients carried six expanded populations, four within the CD4+ subset and two in the CD8+ T cells (fig 3). After six months of treatment and when they were in clinical and laboratory remission, four of the expanded populations remained stable over time, two of them (both in patient B) increased more than 30% of the initial value, and a new expanded population appeared during the disease course in patient D.

Selective decrease of certain BV families in patients with active disease

Patients with active PMR and GCA disclosed TCR BV expansions in both CD4+ and CD8+ T cell subsets. The magnitude of such T cell expansions (in many cases over 10-20% of a particular BV family) might favour the possibility of superantigen stimulation. Superantigens have the property to stimulate a massive proliferation of certain TCR BV families and afterwards they induce the death of a large proportion of these stimulated T cells. As previously shown, CD4+ T cell expansions and especially CD8+ T cell expansions were common in both groups of patients and aged healthy controls. However, simultaneous T cell expansions in both T cell subsets were only present in one patient at the...
therefore, the delay to diagnosis varies between two and four months, mostly depending on the clinical presentation of these syndromes. Therefore, based on the surprising lack of activation surface markers in patients with active disease and on previous results, we decided to search for those BV families that were underrepresented in both T cell subsets in patients with active disease. We arbitrarily chose a value lower than the 25th centile of a healthy young population. Seventeen of the 23 patients with active PMR/GCA disclosed a simultaneous CD4+ and CD8+ T cell depletion for at least one particular BV family (table 5). All the BV families except BV3 showed a significant decrease in at least one patient. However, there was a clear predominance of BV552/S3 (seven patients) followed by BV551, BV6.7, BV8, and BV12 (four patients each). No significant association with any particular HLA-DRB1 molecule was found for BV552/S3 (table 5). Furthermore, BV552/S3 was the only element that did not disclose any single expansion in circulating CD4+ or CD8+ T cells (fig 2).

**DISCUSSION**

There is evidence that the circulating T cell compartment undergoes age associated changes in the distribution of T cell subsets. Therefore, PMR and GCA, two related syndromes that show an extremely close association with age, provide a unique case in which to understand the possible influence of these changes on disease. Our data showed a very similar circulating T cell phenotype among the three study groups, although there were several significant findings. Firstly, patients with active disease showed an inverse relation of naive and memory CD4+ T cells as compared with healthy aged matched controls. Secondly, and more striking, was the finding that patients with active PMR/GCA did not show a higher expression of surface markers indicating activation of T cell subsets than controls. Despite a significant increase in acute phase reactants, the comparison with healthy subjects and also with patients with controlled disease did not show the presence of an activation phenotype in T lymphocytes from patients with active disease. Finally, the severe depletion of CD8+/CD28+ circulating T cells observed in our patient population and also in the aged controls compared with young healthy subjects (data not shown), may contribute to the development of disease in two different ways. Firstly, it may reflect a possible infective agent, especially a viral infection, as responsible for these syndromes. An increasing amount of epidemiological, clinical, and laboratory evidence supports this hypothesis. Secondly, and not mutually exclusive from the first hypothesis, the loss of expression of CD28 with aging may contribute to a state of immunodeficiency that may make a susceptible person prone to develop a disease.

The recognition of certain antigens by specific T cells depends on the TCR, which recognises antigen peptides bound to the MHC on the surface of antigen presenting cells. In autoimmune disorders the triggering antigen is unknown and, therefore, the study of the TCR repertoire use may shed important light on the inciting antigen. Recent studies have demonstrated that the TCR repertoire of circulating T cells is not as extensive as previously thought. Monoclonal antibody and PCR based analyses have shown that circulating T cells include clonal populations, especially within the CD8+ subset. The physiological consequences of this phenomenon are not completely understood, but it has been proposed that these clonal populations are the result of repetitive antigen exposure and might lead to reduced immunoresponsiveness. For this reason, we investigated any skewing in the TCR BV repertoire in our patient group. Our results showed a significant TCR BV expansion of T cells expressing specific TCR BV domains at onset of the disease, after control of the disease with corticosteroids, and also in healthy controls. TCR BV specific expansions constituted a variable, although usually significant, percentage of the total T cell repertoire in both CD4+ and CD8+ T cells, with a majority of expansions exceeding 10% of the T cell repertoire. However, we found no apparent preference for any particular BV gene segment used by the expanded T cell populations. There are several explanations for this finding. One might be the different HLA backgrounds of our patient group. Thus, we did not observe a significant relation between certain HLA-DRB1 alleles and TCR BV expansions. Additionally, other HLA molecules may be involved in the pathogenic mechanisms of these syndromes, or it may be that the size of our sample was not sufficiently large to detect specific associations between HLA and expansions. Another possible explanation is that the triggering agents are multiple and differ between patients. An alternative explanation is that at the time of diagnosis we were missing relevant antigen-specific T cells and only detected bystander T cells. Despite the short time between the onset of symptoms in patients with PMR/GCA and the diagnosis of these syndromes, it is possible that relevant T cells are already undetectable by conventional techniques. This may be the case with flow cytometry, which cannot detect differences in TCR BV use during a conventional antigen-specific T cell response. As previously reported in patients with PMR/GCA, more sensitive techniques such as PCR based methodology are necessary to detect differences in the TCR BV gene usage.

The TCR repertoire has been examined in patients with PMR and GCA in two recent studies. In both of them patients with PMR and GCA carried multiple expanded T cell populations, especially within the CD8+ T cell subset. Although a significant number of these selected clonotypes decreased in size with high dose steroid treatment, all of them persisted despite successful control of the disease with treatment. In contrast with previous studies, we did not find a clear correlation between T cell expansions and...
disease activity. A new analysis carried out in patients with PMR and GCA six months after steroid treatment, when they were asymptomatic, showed no significant changes in the distribution of the TCR BV expansions, suggesting that these expanded populations probably are not directly involved in the disease process.

T cell expansions at disease onset may be explained by specific interactions between T cells that recognise antigens, resulting in the proliferation of T cells expressing a particular TCR element. Dramatic T cell expansions occur more frequently with superantigens. Superantigens have been implicated in the pathogenesis of other vasculitic syndromes, such as Kawasaki’s disease, and other autoimmune disorders, such as rheumatoid arthritis, myasthenia gravis, or Crohn’s disease. Superantigens interact with the immune system by binding in an unrestricted way to the MHC class II proteins and activating T cells through the TCR BV region. Therefore, they cause a massive proliferation of both CD4+ and CD8+ T cells bearing a specific BV element and, then, death of a large proportion of these T cells. Another characteristic of superantigens is that they can activate both CD4+ and CD8+ T cell subsets and, as a consequence of the massive activation and proliferation of T cells, they are responsible for the production of large amounts of proinflammatory cytokines. Hypothetical superantigen stimulation may explain most of the results of the present study (fig 4). It can be postulated that patients with PMR and GCA have encountered a viral or bacterial superantigen specific for a particular BV(s) element(s). In this regard, several micro-organisms have been implicated in the development of PMR and GCA. This encounter would have led to the activation of most T cells bearing this particular BV(s) element(s), a few of which behave as autoreactive T cells, and because of a cross reaction with self antigens would have homed to the arteries or to the synovia, where they help to develop and sustain the inflammatory process. The characteristic strong proliferation of a particular BV element in response to superantigen stimulation is usually followed by a swift decline in the cells expressing the relevant BV. Possibly, the delay in the diagnosis of these two syndromes explains the lack of activation surface markers in our patients with active disease and the simultaneous CD4+ and CD8+ T cell depletion of certain BV families found. The initial superantigen response would stimulate the production of high amounts of proinflammatory cytokines, which are responsible for the main systemic manifestations of these syndromes. Afterwards, a few of the millions of proliferating T cells could include several autoreactive T cells that would proliferate against self antigens.

Different strategies have been used to obtain information about T cells from the inflammatory infiltrate of 17 patients with GCA. The repertoire of these T cells was not clearly restricted (expressed oligoclonal T cells bearing BV2, BV8, BV13.1, BV17, and BV18) except for BV5S2-BJ2S3 T cell clones that were encountered using three different approaches. Furthermore, these T cells had a proliferative response against temporal artery tissue extracts from patients with GCA and PMR but not against normal temporal artery. The development of PMR or GCA almost exclusively in aged subjects would probably depend on many factors related to aging, such as immunosenescence or endocrinosenescence. Moreover, the evolution to a predominantly musculoskeletal disorder, such as PMR, or to a predominantly vascular disease, like GCA, may be determined, at least in part, by genetic factors or by the previous existence of cardiovascular risk factors.

ACKNOWLEDGEMENTS

This work was supported by grants from “Fundación Marqués de Valdecilla” 1998/2000 and Fondo de Investigación Sanitaria (98/0846), Spain.

Authors’ affiliations

V M Martinez-Taboada, R Blanco, V Rodriguez-Valverde, Rheumatology Division, Hospital Universitario “Marques de Valdecilla”, Facultad de Medicina, Universidad de Cantabria, Santander, Spain

www.annrheumdis.com
Immunology Division, 60 Lopez-Hoyos, Bartolome-Pacheco, Blanco, et al

www.annrheumdis.com


Rosane Rivas, Sánchez-Santos, Hírlström, Pons, et al. The role of B lymphocytes in systemic vasculitis: increased T cell receptor


1997;74:689–703.


Selective T cell receptor decrease in peripheral blood T lymphocytes of patients with polymyalgia rheumatica and giant cell arteritis

M Lopez-Hoyos, M J Bartolome-Pacheco, R Blanco, V Rodriguez-Valverde and V M Martinez-Taboada

Ann Rheum Dis 2004 63: 54-60
doi: 10.1136/ard.2003.005900

Updated information and services can be found at:
http://ard.bmj.com/content/63/1/54

These include:

References
This article cites 50 articles, 9 of which you can access for free at:
http://ard.bmj.com/content/63/1/54#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Immunology (including allergy) (5144)
- Connective tissue disease (4253)
- Musculoskeletal syndromes (4951)
- Vasculartis (294)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/